222 related articles for article (PubMed ID: 37027018)
1. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
Zanetta C; Rocca MA; Meani A; Martinelli V; Ferrè L; Moiola L; Filippi M
J Neurol; 2023 Jul; 270(7):3553-3564. PubMed ID: 37027018
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
Aerts S; Khan H; Severijns D; Popescu V; Peeters LM; Van Wijmeersch B
Mult Scler Relat Disord; 2023 Jul; 75():104735. PubMed ID: 37192586
[TBL] [Abstract][Full Text] [Related]
3. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Rolfes L; Pfeuffer S; Huntemann N; Schmidt M; Su C; Skuljec J; Aslan D; Hackert J; Kleinschnitz K; Hagenacker T; Pawlitzki M; Ruck T; Kleinschnitz C; Meuth SG; Pul R
Mult Scler Relat Disord; 2022 Aug; 64():103931. PubMed ID: 35690010
[TBL] [Abstract][Full Text] [Related]
4. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
[TBL] [Abstract][Full Text] [Related]
5. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
[TBL] [Abstract][Full Text] [Related]
6. High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
Negrotto L; Iut VC; Etchepare A; D'Eramo M; Grinspan A; Assefi A
Mult Scler Relat Disord; 2022 Dec; 68():104403. PubMed ID: 36544327
[TBL] [Abstract][Full Text] [Related]
7. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal.
Santos M; Sequeira J; Abreu P; Guerreiro R; Santos M; Ferreira J; Brum M; Ladeira F; Leitão L; Dias R; Sá MJ; Salgado V; Capela C; de Sá J
Clin Neuropharmacol; 2023 May-Jun 01; 46(3):105-111. PubMed ID: 37191564
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study.
Petracca M; Ruggieri S; Barbuti E; Ianniello A; Fantozzi R; Maniscalco GT; Andreone V; Landi D; Marfia GA; Di Gregorio M; Iodice R; Sinisi L; Maida E; Missione R; Coppola C; Bonavita S; Borriello G; Centonze D; Lus G; Pozzilli C; Signoriello E
Neurol Ther; 2022 Sep; 11(3):1193-1208. PubMed ID: 35653061
[TBL] [Abstract][Full Text] [Related]
10. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
Adamec I; Brecl Jakob G; Rajda C; Drulović J; Radulović L; Bašić Kes V; Lazibat I; Rimac J; Cindrić I; Gržinčić T; Abičić A; Barun B; Gabelić T; Gomezelj S; Mesaroš Š; Pekmezović T; Klivényi P; Krbot Skorić M; Habek M
J Neuroimmunol; 2023 Sep; 382():578164. PubMed ID: 37536052
[TBL] [Abstract][Full Text] [Related]
11. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
[TBL] [Abstract][Full Text] [Related]
12. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
Rauma I; Viitala M; Kuusisto H; Atula S; Sipilä JOT; Ryytty M; Soilu-Hänninen M; Järvinen E
Mult Scler Relat Disord; 2022 May; 61():103755. PubMed ID: 35483129
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
Pfeuffer S; Rolfes L; Hackert J; Kleinschnitz K; Ruck T; Wiendl H; Klotz L; Kleinschnitz C; Meuth SG; Pul R
Mult Scler; 2022 Feb; 28(2):257-268. PubMed ID: 33975489
[TBL] [Abstract][Full Text] [Related]
14. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
15. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
[TBL] [Abstract][Full Text] [Related]
16. A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine.
Al-Hashel J; Ahmed SF; AlMojel M; Alroughani R
Clin Neurol Neurosurg; 2023 Sep; 232():107885. PubMed ID: 37459794
[TBL] [Abstract][Full Text] [Related]
17. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
Bose G; Rush C; Atkins HL; Freedman MS
Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
López-Real AM; Gonzalez I; Solar DM; Oterino A; Costa E; Pato A; Llaneza MA; García-Estévez DA; Rodriguez-Regal A; Rodriguez M; Peña J
Mult Scler Relat Disord; 2023 Jul; 75():104762. PubMed ID: 37229800
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
